Nitrofurantoin Monohyd/M-Cryst
Brand name: Nitrofurantoin Mono-Macro
Rank #386 of 500 drugs by total cost
$24.4M
Total Cost
1,173,249
Total Claims
$24.4M
Total Cost
45,497
Prescribers
$21
Cost per Claim
860,796
Beneficiaries
1,225,499
30-Day Fills
$537
Avg Cost/Provider
26
Avg Claims/Provider
About Nitrofurantoin Monohyd/M-Cryst
Nitrofurantoin Monohyd/M-Cryst (sold as Nitrofurantoin Mono-Macro) was prescribed 1,173,249 times by 45,497 Medicare Part D providers in 2023, costing the program $24.4M. At $21 per claim, this is a relatively affordable medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 383 | Flecainide Acetate (Flecainide Acetate) | $25.1M | 412,334 |
| 384 | Pioglitazone Hcl (Pioglitazone Hcl) | $24.8M | 1,182,614 |
| 385 | Fremanezumab-Vfrm (Ajovy Autoinjector) | $24.7M | 29,389 |
| 386 | Nitrofurantoin Monohyd/M-Cryst (Nitrofurantoin Mono-Macro) | $24.4M | 1,173,249 |
| 387 | Pegfilgrastim (Neulasta) | $24.4M | 3,096 |
| 388 | Linagliptin/Metformin Hcl (Jentadueto) | $24.3M | 33,018 |
| 389 | Ocrelizumab (Ocrevus) | $24.2M | 639 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology